drugset
drugset / Trial / NCT01842269

Evaluate the Efficacy and Safety of My-Rept® Tablet vs. My-Rept® Capsule in Combination With Tacrolimus in Kidney Transplant Patients

NCT01842269 ↗

Phase 4 Completed 156 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupOpen-labelTreatment

Summary

Efficacy and Safety of My-Rept® Tablet(Mycophenolate Mofetil 500mg/Tab.) versus My-Rept® Capsule(Mycophenolate Mofetil 250mg/Cap.) in Combination with Tacrolimus in Kidney Transplant Patients

Timeline

Start
2013-01
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycophenolate Mofetil Small molecule 250 mg Oral
Subject Mycophenolate Mofetil Small molecule 500 mg Oral

Indications

No indication recorded.